Morgan Stanley raised the firm’s price target on BrightSpring Health (BTSG) to $32 from $25 and keeps an Overweight rating on the shares. Last week’s Stars results were “encouraging” for the sector and Managed Care Organization sentiment has “improved slightly,” but there is “still a lot to prove” as the focus turns to utilization and early reads on 2026, the analyst tells investors in a Q3 earnings preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services: Strong Buy Rating Backed by Robust Pharmacy Segment and Strategic Growth Initiatives
- BrightSpring Health price target raised to $33 from $27 at Wells Fargo
- UnitedHealth (UNH) Divests Home Health and Hospice Assets Worth $146.5M to Pennant
- BrightSpring Health price target raised to $31 from $27.50 at BofA
- BrightSpring Health price target raised to $30 from $25 at Deutsche Bank